15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study

Intensive Care Medicine

Volumn 46, Issue 7, 2020, Pages 1472-1474

  Wang, Ke ^a,b   Zhang, Zhiguo ^a   Yu, Muqing ^a,b   Tao, Yu ^a,b   Xie, Min ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARBIDOL; C REACTIVE PROTEIN; FERRITIN; GLUCOCORTICOID; LACTATE DEHYDROGENASE; LOPINAVIR PLUS RITONAVIR; LOPIRAZEPAM; LORAZEPAM; RITONAVIR;

AGING; ASSISTED VENTILATION; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONAVIRUS DISEASE 2019; CORTICOSTEROID THERAPY; DIABETES MELLITUS; EPIDEMIC; GERIATRIC PATIENT; HEART ARREST; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOXIA; LETTER; LYMPHOCYTOPENIA; MORTALITY RATE; NONINVASIVE VENTILATION; RISK FACTOR; SEX DIFFERENCE; SMOKING; AGE; AGED; BETACORONAVIRUS; COMBINATION DRUG THERAPY; COMPLICATION; CORONAVIRUS INFECTION; CRITICAL ILLNESS; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MULTIPLE ORGAN FAILURE; PANDEMIC; PROPORTIONAL HAZARDS MODEL; VIRUS PNEUMONIA;

AGE FACTORS; AGED; BETACORONAVIRUS; CHINA; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HOSPITAL MORTALITY; HUMANS; LORAZEPAM; LYMPHOPENIA; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PANDEMICS; PNEUMONIA, VIRAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RITONAVIR;

EID: 85083803739     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-020-06047-w     Document Type: Letter

References (5)

1. Li Q, Guan X, Wu P et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New Engl J Med 382:1199–1207 DOI: 10.1056/NEJMoa2001316
2. Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062 DOI: 10.1016/S0140-6736(20)30566-3
3. Li XC, Xu SY, Yu MQ et al (2020) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 10.1016/j.jaci.2020.04.006 DOI: 10.1016/j.jaci.2020.04.006
4. Cao B, Wang Y, Wen D et al (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 10.1056/NEJMoa2001282 DOI: 10.1056/NEJMoa2001282
5. Moreno G, Rodriguez A, Reyes LF et al (2018) Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med 44:1470–1482 DOI: 10.1007/s00134-018-5332-4